Primary Inguinal Hernia
Conditions
Brief summary
The primary objective of this study is to evaluate patient quality-of-life (QOL) after inguinal hernia repair. Carolinas Comfort Scale (CCS) assessments will be held at regular intervals. The secondary objective of the study is to follow short-term and long-term study-related complications/adverse events.
Interventions
Sponsors
Study design
Eligibility
Inclusion criteria
* Scheduled to undergo routine inguinal hernia repair * Competent to give consent * Clinically relevant inguinal hernia (classification: NYHUS I, II, IIIa) * Defect size at operation is between 5mm and 35mm * Diagnosed with unilateral, direct, indirect or mixed inguinal hernia * Primary hernia at the operative site * Male or female * Life expectancy of at least 12 months * At least 18 years of age
Exclusion criteria
* Signs of obvious local or systemic infection * Any previous surgery on the hernia operative site * Hernia is not in the inguinal area * Hernia is not identified as indirect or direct * Femoral hernias * Known collagen disorder * Presenting with unstable angina or NYHA class of IV * Known Pregnancy * Active drug user * Recurrence of a repair by any method * Patients with giant inguinoscrotal hernia or abdominal wall defect \>35 mm in diameter - e.g. large direct or combined inguinal hernia type Nyhus IIIb / EHS P L/M 1/2/3 * Immunosuppression, prednisone\>15 mg/day, active chemotherapy * End stage renal disease * Abdominal ascites * Skin infection in area of surgical field * BMI \>35 * Peritoneum cannot be closed
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Measure changes from baseline in Carolina Comfort Scale (CCS) scores at specified time intervals | 1 week, 3, 6, 9, 12, 18, 24, and 36 months. | Measure quality of life for patients undergoing inguinal hernia repair. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Evaluate the 14-day pain and medication log | 14 days | Patient will record pain score and medications for 14 consecutive days. |
Other
| Measure | Time frame |
|---|---|
| Study-related complications/adverse events | 3 years |
Countries
Austria, Italy, United States